Fluoxymesterone

Drug Profile

Fluoxymesterone

Alternative Names: Androfluorene; Androfluorone; Android-F; Androsterolo; Fluotestin; Fluoxymesterone CIII; Halotestin; Ora-Testryl; Oralsterone; Oratestin; Stenox; Testoral; Ultandren

Latest Information Update: 26 Aug 2004

Price : $50

At a glance

  • Originator Unknown
  • Developer Atlantil Labs; Bouty; Brown Pharmaceuticals; Novartis; Pfizer; Rosemont Pharmaceutical Corporation; Sanofi; Sanofy-Midy; Squibb
  • Class Androstenediols; Fluorinated steroids; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Delayed puberty; Hypogonadism

Most Recent Events

  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 24 Nov 2000 A study in patients with breast cancer has been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top